Format

Send to

Choose Destination
Hum Vaccin Immunother. 2014;10(1):52-63. doi: 10.4161/hv.26568. Epub 2013 Sep 24.

Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Author information

1
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA.

Abstract

The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.

KEYWORDS:

adjuvant; allogeneic; cancer; clinical trials; immunotherapy; vaccine

PMID:
24064957
PMCID:
PMC4181031
DOI:
10.4161/hv.26568
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center